HRT Financial’s Anavex Life Sciences AVXL Stock Holding History

HRT Financial’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38K	Sell	15,000 -24,000	-62%	-$71K	﹤0.01%	3828
2026 Q1	$119K	Buy	+39,000	New	+$169K	﹤0.01%	3318

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's AVXL Position: Q2 2026 in Review

HRT Financial sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 657,877 shares — an estimated $1.95M sold.

HRT Financial first reported a position in AVXL in Q2 2022 and held it in 4 quarters. The position peaked at $2.02M in Q1 2026. 180 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

HRT Financial reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 657,877 Anavex Life Sciences shares in Q2 2026, an estimated $1.95M.
HRT Financial first reported a position in Anavex Life Sciences in Q2 2022 and held it in 4 quarters.
HRT Financial's Anavex Life Sciences position peaked at $2.02M in Q1 2026.
180 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.